Vericel to Present at Canaccord Genuity and ARM Investor Conferences
CAMBRIDGE, Mass., March 18, 2015 (GLOBE NEWSWIRE) -- Vericel Corporation (Nasdaq:VCEL), a leading developer of patient-specific expanded cellular therapies for the treatment of severe diseases and conditions, today announced that it will present at the following investor conferences later this month:
Canaccord Genuity Musculoskeletal Conference in Las Vegas on Tuesday, March 24, 2015; Vericel president and CEO Nick Colangelo will present a corporate update at 6:00pm EDT with a live webcast at http://wsw.com/webcast/canaccord17/vcel.
- Alliance for Regenerative Medicine 2015 Regen Med Investor Day in New York on Wednesday, March 25, 2015; Vericel COO Dan Orlando's will present a corporate update at 2:40pm EDT with a live webcast at http://arminvestorday.com/webcast.
About Vericel Corporation
Vericel Corporation (formerly Aastrom Biosciences, Inc.) is a leader in developing patient-specific expanded cellular therapies for use in the treatment of patients with severe diseases and conditions. The company markets two autologous cell therapy products in the United States: Carticel® (autologous cultured chondrocytes), an autologous chondrocyte implant for the treatment of cartilage defects in the knee, and Epicel® (cultured epidermal autografts), a permanent skin replacement for the treatment of patients with deep-dermal or full-thickness burns comprising greater than or equal to 30 percent of total body surface area. Vericel is also developing MACI™, a third-generation autologous chondrocyte implant for the treatment of cartilage defects in the knee, and ixmyelocel-T, a patient-specific multicellular therapy for the treatment of advanced heart failure due to ischemic dilated cardiomyopathy. For more information, please visit the company's website at www.vcel.com.
CONTACT: Chad Rubin The Trout Group email@example.com (646) 378-2947 or Lee Stern The Trout Group firstname.lastname@example.org (646) 378-2922